Non Motor Symptoms in Glucocerebrosidase-related Parkinson's Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-07-01

Study Completion Date

2026-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to describe non motor symptoms in a prospective study of patients with Parkinson's disease associated to glucocerebrosidase (GBA-PD) mutations.

The main questions it aims to answer are:

* Do GBA-PD patients have a greater burden of non motor symptoms?
* How do these non motor symptoms evolve during a prospective follow up of two years?
* Are these non motor symptoms different from those that affect Parkinson's disease patients without glucocerebrosidase mutations (non GBA-PD), in prevalence, severity and type?
* Do these non motor symptoms correlate with objective measures such as posturography or speed reaction tests?
* Is there a test or combination of tests that can predict the appearance of early or severe non motor symptoms?

For this reason researchers will compare the GBA-PD group of patients with a group of non mutated GBA Parkinson disease.

Participants will undergo a neurological and neuropsychological evaluation with different tests in subsequent visits for a total of 2 years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Exploring Brain Molecular Imaging and Blood Biomarkers in Subjects With Glucocerebrosidase Mutations: Toward a Precision Medicine Approach to Characterize Parkinson's Disease Clinical Trajectories

NCT06167603

Parkinson Disease

RECRUITING

Evaluation of Functional and Biochemical Effectiveness of a Strength Training Protocol in Parkinson's Disease

NCT07095400

Parkinson Disease

NOT_YET_RECRUITING NA

Performance of the Paragit Sleeve to Measure and Monitor Motor Symptoms in Patients With Parkinson's Disease

NCT06490861

Parkinson Disease

RECRUITING NA

Sensorimotor Integration in Monogenic Parkinson-dystonia Syndromes

NCT05713721

Parkinson Dystonia DYT3 +3 more

UNKNOWN

Prodromal Parkinsonian Features in GBA1 Mutation Carriers

NCT05253560

Gaucher Disease, Type 1 Healthy

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Parkinson's disease is the second most prevalent neurodegenerative disorder worldwide. Up to date, the main risk factor for its development is carrying an heterozygous mutation in glucocerebrosidase gene (GBA). GBA codifies for a GC-ase protein that takes part in lysosomal function. The homozygous mutation of this gene gives rise to Gaucher disease, which is a lysosomal disorder. This gene has also been associated with Lewy body dementia.

The presence of an heterozygous mutation in GBA in Parkinson's disease can be found in up to 5-15% of the patients, depending on age and ethnicity. It has been described that those patients carrying the mutation can have an earlier debut of the disease.

According to non motor symptoms, patients are prone to develop earlier and more severe motor symptoms. This has been studied specially in cognitive impairment but also dysautonomia, impulse control disorder and others.

In relation to cognitive impairment these patients usually develop an earlier and more severe affection, reaching dementia states earlier in the disease. Some studies have described a worsening in cognitive function in GBA mutated patients after deep brain stimulation (DBS) to treat parkinsonian symptoms. This prevents patients from being candidates to therapies such as DBS.

For this reason, the investigators consider it important to make a proper description of non motor symptoms in GBA mutated parkinsonian patients, since this finding can help to delineate the prognosis and choose individualized treatments, regarding the suggested differences with other Parkinson's disease patients.

It is an observational prospective cohort study. Participants will be collected from a subgroup of patients that have agreed to undertake a genetic test including a panel of genes associated to Parkinson's disease.

According to the results, patients will be subdivided in two groups according to their genetic status:

* GBA heterozygous mutations
* Absence of genetic mutations

These patients will undergo neurologic evaluations, neuropsychological evaluations and self-administered evaluations. There will be no intervention.

The pharmacologic and other type of treatment assessments will be conducted during their regular follow up with their neurologist.

These visits will be repeated every 6 months for a total of 2 years. Total of 5 visits for each patient.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Glucocerebrosidase associated Parkinson's disease

Patients aged under 70 when symptoms began or with family history of Parkinson's disease who underwent a genetic testing including a pannel of 64 genes associated with Parkinson's diasease and who tested positive for heterozygous glucocerebrosidase mutation.

Tests on non motor symptoms

Intervention Type OTHER

Neurological, neuropsychological and self-administered tests on non motor symptoms, including posturography and speed reaction times.

Non glucocerebrosidase associated Parkinson's diasease

Patients aged under 70 when symptoms began or with family history of Parkinson's disease who underwent a genetic testing including a pannel of 64 genes associated with Parkinson's diasease and who tested negative for all the mutations in the pannel.

Tests on non motor symptoms

Intervention Type OTHER

Neurological, neuropsychological and self-administered tests on non motor symptoms, including posturography and speed reaction times.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tests on non motor symptoms

Neurological, neuropsychological and self-administered tests on non motor symptoms, including posturography and speed reaction times.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged over 18 years old.
* Fulfill Parkinson's disease criteria of Movement Disorder Society 2015.
* Parkinson's disease symptoms began before they were 70 and/or Parkinson's disease family history.
* Underwent a genetic test of Parkinson's disease related genes.
* Heterozygous mutation of glucocerebrosidase gene (only cases).
* Absence of mutation in the Parkinson's disease genetic test (only controls).

Exclusion Criteria

* Suspicion of atypical parkinsonism.
* Personal history of other neurodegenerative disorders such as Alzheimer's disease.
* Personal history of significant cerebrovascular damage, intracraneal lessions or important craneoencephalic trauma.
* Deep brain stimulation treatment for Parkinson's disease.
* Moderate or severe dementia that precludes from performing the tests.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No